Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Loseto, Giacomo  [Clear All Filters]
2013
Mele G, Greco M, Coppi MRosaria, Loseto G, Melpignano A, Mauro S, Quarta G. Small-Sized Clone of T Cells in Multiple Myeloma Patient after Auto-SCT: T-LGL Leukemia Type or Clonal T-Cell Aberration?. Case Rep Hematol. 2013;2013:417353.
2014
De Tullio G, De Fazio V, Sgherza N, Minoia C, Serratì S, Merchionne F, Loseto G, Iacobazzi A, Rana A, Petrillo P, et al. Challenges and Opportunities of MicroRNAs in Lymphomas. Molecules. 2014;19(9):14723-14781.
2021
Morabito F, Tripepi G, Del Poeta G, Mauro FRomana, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Varettoni M, et al. Assessment of the 4-factor score: retrospective analysis of 586 cll patients receiving ibrutinib. A campus cll study. Am J Hematol. 2021.
Morabito F, Tripepi G, Del Poeta G, Mauro FRomana, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, et al. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials. Am J Hematol. 2021.
Morabito F, Del Poeta G, Mauro FRomana, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, et al. TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases. Am J Hematol. 2021.
2023
Bavaro DFiore, Diella L, Belati A, Metrangolo G, De Santis L, Spada V, Camporeale M, Dargenio A, Brindicci G, Balena F, et al. Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study. Viruses. 2023;15(5).
Minoia C, Diella L, Perrone T, Loseto G, Pelligrino C, Attolico I, Pasciolla C, Totaro V, De Candia MStella, Spada V, et al. Oral anti-viral therapy for early COVID-19 infection in patients with haematological malignancies: A multicentre prospective cohort. Br J Haematol. 2023.
Gaudio F, Loseto G, Bozzoli V, Scalzulli PRosario, Mazzone AMaria, Tonialini L, Fesce V, Quintana G, De Santis G, Masciopinto P, et al. A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin's lymphoma. Ann Hematol. 2023.